Oral formulations of Edaravone and method of manufacturing thereof

A pharmaceutical composition, comprising an oral suspension, wherein the oral suspension comprises:

• edaravone or a pharmaceutically acceptable salt thereof, in a concentration of at least 2% w/v;
• and the following pharmaceutically acceptable excipients;
• a. an antioxidant, in a concentration of not more than 3.5% w/v;
• b. a wetting agent, in a concentration of not more than 20% w/v;
• c. a suspending or thickening agent, in a concentration of not more than 2% w/v;
• d. an anti-foaming agent, in a concentration ranging from 0% w/v to 1% w/v;
• e. a sweetening, coloring, or flavouring agent, in a concentration ranging from 0% w/v to 0.5% w/v;
• and
• f. a vehicle, in a concentration of at least 65% w/v;
• wherein each concentration is based on the total amount of the formulation;
• wherein Edaravone is in a micronized form in the oral suspension;
• and
• wherein the particle size D100 of the micronized form of Edaravone is less than 8000 nm.